GLP-1 GUIDE — GENERIC DRUG TIMELINE

When Will GLP-1 Generics Be Available? The 2026 Timeline, by Drug

Published: June 15, 2026 · Last reviewed: June 15, 2026

By The RX Index Editorial Team · The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers.

Last verified: June 15, 2026

So, when will GLP-1 generics be available? Here’s the part almost every other page buries: a few are already here. They’re just not the ones you’re probably waiting for.

As of June 15, 2026, there is no generic Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, or Foundayo for sale in the United States. For semaglutide (the drug in Ozempic and Wegovy), a true U.S. generic is realistically an early-2030s story — around 2032. For tirzepatide (Mounjaro and Zepbound), it’s even further out, likely 2036 or later. But older GLP-1 medicines already have FDA-approved generics — including the first generic GLP-1 ever approved for weight loss.

That gap — between what’s real now, what’s years away, and what’s a scam dressed up as a “generic” — is the whole game. Below, we map every major GLP-1 in one place, explain what a recent FDA decision actually means, and show you the cheapest legitimate way to get treatment now if you’d rather not wait until the 2030s.

The GLP-1 generic tracker: what’s available right now

Here’s the fast answer, drug by drug. (“GLP-1” is a class of medications — short for glucagon-like peptide-1 receptor agonists — not a single drug. That’s why the answer changes depending on which one you mean.)

One thing to lock in before we go further: an FDA-approved generic is not the same as a “compounded” version you see advertised online. We’ll explain the difference — and the scams — in detail below, because this is where people lose money and take risks they don’t need to.

When will GLP-1 generics be available? The short answer

We’re going to be straight with you about something: no one can give you a guaranteed launch date for generic Ozempic, Wegovy, Mounjaro, or Zepbound. Patents get challenged. Lawsuits settle. Factories take time to scale. Any “exact date” you see online is a guess.

But that uncertainty is exactly why we built this page the way we did. Instead of one fuzzy date, we sort every GLP-1 into clear buckets: available now, cleared but not for sale yet, available abroad but not in the U.S., and not a real generic at all. That way you can make a smart decision today instead of waiting on a date that may never land the way you hope.

Two numbers anchor everything:

• 1

  Semaglutide (Ozempic, Wegovy): about 2032. The key U.S. patent that blocks a generic is expected to expire in 2032 (Novo Nordisk’s own 2025 financial filing lists 2032 for its semaglutide products; The Globe and Mail; patent analysts at I-MAK put the main compound patent at December 2031).

• 2

  Tirzepatide (Mounjaro, Zepbound): about 2036. The main patent is expected to run until around January 2036, with follow-on patents on the device and formulation possibly stretching protection toward 2041 (GreyB; I-MAK).

Wait — some GLP-1 generics already exist?

This is the part that surprises people. “Generic GLP-1” isn’t a future thing. It’s already happening — just with the older medications.

Generic exenatide (Byetta). In November 2024, the FDA approved the first-ever generic GLP-1: a generic version of Byetta (exenatide), made by Amneal Pharmaceuticals. Exenatide is an older diabetes drug taken as a shot twice a day. It works, but it’s not the once-weekly, big-weight-loss drug most searchers have in mind.

Generic liraglutide (Victoza). On December 23, 2024, the FDA approved a generic of Victoza (liraglutide), made by Hikma Pharmaceuticals, for type 2 diabetes in patients 10 and older (FDA). (An “authorized generic” version of Victoza — the brand drug sold without the brand name — had launched earlier in 2024.) Liraglutide is a once-daily shot — also older.

Generic Saxenda — the big one. On August 28, 2025, Teva launched a generic version of Saxenda (liraglutide), which the company describes as the first generic GLP-1 specifically approved for weight loss (Teva). For the first time, there’s a lower-cost, FDA-approved GLP-1 generic on a weight-loss label.

So why might this still not be what you want?

Here’s our one honest catch: liraglutide is older, it’s a daily injection, and it tends to produce less weight loss than semaglutide or tirzepatide. It is not a generic version of Wegovy or Zepbound. If you’ve had your heart set on a cheap copy of the newer drugs, this isn’t it.

But don’t write it off, either. For the right person — someone who’s cost-first, okay with a daily shot, and wants something FDA-approved today instead of a 2030s wait — generic liraglutide can be a genuinely good conversation to have with a clinician. And if it’s not your fit, you still have current options we’ll cover below.

When will generic Ozempic be available?

In April 2026, Apotex (working with a partner called Orbicular) became the first company to win FDA tentative approval for a generic semaglutide injection — a generic Ozempic — covering all the marketed strengths (Apotex).

What “tentative approval” means in plain English: the FDA reviewed the generic and decided it meets the agency’s standards for quality, safety, and effectiveness. But it legally cannot be sold yet because the brand’s patents and exclusivity haven’t expired (FDA). Think of it as a runner who’s passed every check and is standing at the starting line — but the gun hasn’t gone off. That gun is the patent clock, and for Ozempic it’s expected to fire around 2032 (The Globe and Mail).

There’s a small upside hidden in this. A first generic company that qualifies can earn 180 days of market exclusivity — roughly six months as the only generic on the shelf before others can fully compete. Apotex being first in line is a sign the pipeline is real. It’s just not a 2026 or 2027 event.

“But I read Ozempic’s patent expires in 2026”

You probably did — and it’s half true. Semaglutide’s patents are expiring in some countries in 2026 (more on that below). But U.S. patent timing is different, and a patent expiring in another country does nothing to create a legal generic Ozempic in an American pharmacy.

A nerdy detail that’s actually good news for your wallet

A lot of pages claim semaglutide must take the slow “biosimilar” path. (A biosimilar is a near-copy of a complex biologic drug; it costs far more to develop and saves less than a regular generic.) The evidence points the other way. Apotex’s generic Ozempic went through a regular generic application — an ANDA, short for Abbreviated New Drug Application, the standard route for generics — not the biosimilar route.

Why care? Because regular generics drive prices down hard once competition shows up. The FDA’s own data: one generic competitor cuts prices about 30%, and five competitors cut them nearly 85% (FDA). The hold-up is patents — not the science.

When will generic Wegovy be available?

People reasonably ask: “Ozempic and Wegovy are both semaglutide — so won’t one generic cover both?”

Not exactly. Ozempic is approved for type 2 diabetes. Wegovy is approved for weight management. They both contain semaglutide, but they’re sold as different products, at different doses, on different labels. A pharmacy can only swap in a generic that’s approved against a specific brand product. The FDA requires a generic to match the brand it copies in dosage form, strength, route, and intended use (FDA). So a generic built to reference Ozempic doesn’t automatically become a legal stand-in for Wegovy.

Canada is the perfect real-world example. Canada now has a generic semaglutide — but it’s approved as a generic Ozempic for diabetes, not as a generic Wegovy for weight loss (Health Canada). Same molecule, different lane.

What about the Wegovy pill?

Novo Nordisk launched an oral (pill) version of Wegovy in January 2026. A pill adds another layer of patents and formulation challenges, which usually means an even longer wait for a generic. For now, there’s no U.S. generic of oral semaglutide in any form — including Rybelsus, the diabetes pill.

When will generic Mounjaro or Zepbound be available?

If you’re waiting on a generic Zepbound, settle in. This one’s the marathon.

Why tirzepatide is later than semaglutide: it’s a newer drug, so it’s earlier in its patent life. The main compound patent is expected to run until around 2036 (GreyB; I-MAK), and additional patents covering the injector pen and formulation could push real-world competition toward 2039–2041 (GreyB). That’s potentially a decade-plus away.

A warning about “generic tirzepatide” ads

If you see a website selling “generic tirzepatide” or “generic Zepbound” today, here’s the truth: there is no FDA-approved generic tirzepatide. So whatever is being sold is not that. It’s usually a compounded product (custom-mixed by a pharmacy) — which is a completely different thing, and not legally a “generic.” We break this down in the next section, because it’s where people get burned.

What to do if Zepbound is what you actually want

Waiting until 2036 isn’t a plan for most people. The good news: tirzepatide got dramatically cheaper to access in 2026 through the maker’s own programs. Eli Lilly now sells Zepbound vials directly to cash-paying patients for $299–$449 a month depending on dose, through its LillyDirect platform (CNBC) — down from over $1,000 at list price. That’s not a generic, but it’s a real, FDA-approved path that didn’t exist a year ago. More on current prices below.

Is compounded semaglutide or tirzepatide the same as a generic?

This is the most important section on the page, because it’s where “I want a cheap generic” turns into a real risk if you’re not careful.

A quick vocabulary check, because the words get blurred on purpose by some sellers:

The FDA is blunt about this: compounded drugs are not FDA-approved, the agency does not review their safety, effectiveness, or quality before they’re marketed, and they are not the same as generic drugs, which are FDA-approved (FDA).

The compounding rules just changed — a lot

For a couple of years, compounded semaglutide and tirzepatide were widely available because the brand drugs were in official shortage, which temporarily opened a legal door for large pharmacies to mass-produce copies. That door is closing:

• The FDA declared the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025 (FDA). When a shortage ends, the legal basis for large-scale compounding goes away.
• On April 30, 2026, the FDA proposed permanently removing semaglutide, tirzepatide, and liraglutide from the “503B bulks list” — the list that lets large outsourcing pharmacies make these drugs in bulk. The FDA opened a public comment period through June 29, 2026, and said it would weigh the comments before deciding. As of our June 15, 2026 verification date, the proposal was not final — but if finalized, it would block 503B facilities from compounding these three drugs from bulk ingredients (Pharmacy Times).
• The FDA issued warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products. The two main problems cited: claims implying the compounded drug is the same as an FDA-approved one, and hiding who actually compounded it (FDA).
• In its lawsuits against compounders, Novo Nordisk has reported testing that found some compounded samples with impurity levels as high as 86% (Drug Topics). Treat that as manufacturer-reported evidence from litigation — not an FDA finding — but it’s a real reason the agency and doctors are concerned.

The bottom line for you: compounded is not a generic, it was never FDA-approved, and the rules are tightening fast. That’s exactly why we don’t point you toward it as a shortcut on this page.

The “generic semaglutide” wording trap

Read this twice: “semaglutide” is the drug’s name, but the word “semaglutide” on a checkout page does not prove the product is an FDA-approved generic Ozempic or Wegovy. A site can legally list “semaglutide” while selling a compounded product that the FDA never reviewed.

Red flags that a “generic GLP-1” offer is risky

Walk away if you see any of these:

• Claims it’s “the same as Ozempic” or “the same as Wegovy”
• No prescription or no real clinician screening required
• A price that’s too good to be true
• “Research use only” sold with dosing instructions for people
• “Semaglutide sodium” or “semaglutide acetate” — these are unapproved salt forms the FDA has flagged
• No clear, licensed U.S. pharmacy named
• Product that arrives warm or without proper cold packaging

The FDA’s BeSafeRx program is a free tool for checking whether an online pharmacy is legitimate. When in doubt, use it.

What countries already have generic semaglutide?

Canada. On April 28, 2026, Health Canada became the first G7 regulator to approve a generic semaglutide (made by Dr. Reddy’s), and approved a second — Apotex’s Apo-Semaglutide Injection — on May 1, 2026 (Health Canada). But both are approved as a generic Ozempic for type 2 diabetes — the weight-loss product, Wegovy, is still patent-protected in Canada.

India. Novo Nordisk’s patent on semaglutide expired in India in March 2026, and multiple Indian drugmakers were expected to launch low-cost generics, some at a tiny fraction of U.S. prices (Reuters).

Why you can’t just import “generic Ozempic” from abroad. A drug being approved in another country does not make it FDA-approved or safe for you. The FDA says that, in most cases, it is illegal for individuals to import drugs into the U.S. for personal use, and that it cannot guarantee the safety or effectiveness of medicine bought from foreign sources (FDA). Online “international pharmacy” ads are also a common source of counterfeit products.

Why are GLP-1 generics taking so long?

None of this is meant to discourage you. It’s meant to explain why “just wait for the generic” is a weak plan for a drug you might need now — and why understanding your real options today is worth more than a rumored launch date.

Should you wait for GLP-1 generics?

This is really the decision underneath your search: wait, or start now? Here’s a simple way to think it through.

The honest takeaway: for most people who need help with weight or blood sugar now, waiting on a generic isn’t the move. The drugs you’d actually wait for are years out, and the things you can do today have gotten much more affordable.

What are the cheapest legitimate GLP-1 options right now?

Here’s a snapshot of the real options, verified as of June 15, 2026. (Prices and offers change often — always confirm at the official program page before you commit.)

Sources: NovoCare, LillyDirect, Eli Lilly, CNBC, KFF, and CMS. Confirm current pricing at each program’s official page.

The new Medicare option, explained

If you’re on Medicare, this is big. Starting July 1, 2026, a temporary program called the Medicare GLP-1 Bridge lets eligible Part D members get certain weight-loss drugs — all forms of Wegovy and Foundayo, plus the Zepbound KwikPen — for a flat $50 a month, no matter the dose (CMS). To qualify, you need to be enrolled in a Part D plan and meet weight criteria (a BMI of 35 or higher, or 27 or higher with another condition like heart disease or prediabetes). Two honest catches: the program runs only through the end of 2027, and that $50 copay does not count toward your Part D deductible or your yearly out-of-pocket cap.

The FDA-approved generic that’s already here

If cost is your top concern and you’re open to an older daily shot, generic liraglutide is worth asking a clinician about. It’s the one true GLP-1 generic available on a weight-loss label today. It won’t match the newer drugs on results, but it’s FDA-approved and lower-cost — a real option, not a workaround. For more alternatives, see our cheapest GLP-1 without insurance guide.

Insurance, prior authorization, and appeals

Coverage is often the fastest path to a low price — if you can get it. Whether a GLP-1 is covered usually depends on why you’re taking it (diabetes vs. weight) and your specific plan’s rules. If you were denied, an appeal or a prior-authorization fix can sometimes unlock coverage faster than a generic ever would.

Disclosure: The RX Index may earn a commission if you choose certain providers, including Ro, through links on this page or after using our quiz. It costs you nothing extra. Our generic timeline and safety guidance are based on source verification, not commissions — and we don’t recommend compounded “generic” sellers here, regardless of payout.

What we actually verified

Here’s exactly what we confirmed for this update (June 15, 2026):

• No FDA-approved generic for semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) — confirmed via FDA, manufacturer pages, and drug databases.
• Generic exenatide (Amneal, Nov 2024), generic liraglutide/Victoza (Hikma, Dec 2024), and generic Saxenda (Teva, Aug 2025) — confirmed via FDA and Teva.
• Apotex’s first U.S. FDA tentative approval for a generic Ozempic (April 2026) and what tentative approval means — confirmed via Apotex and the FDA.
• Semaglutide ~2032 and tirzepatide ~2036 patent windows — confirmed via Novo Nordisk’s financial filing, patent analyses, and reporting.
• The FDA’s April 30, 2026 proposal on 503B compounding, its 30 telehealth warning letters, and its warnings on unapproved GLP-1 products — confirmed via the FDA and Pharmacy Times.
• Canada’s first-G7 generic semaglutide approvals (diabetes) and India’s March 2026 patent expiry — confirmed via Health Canada and Reuters.
• Current cash prices, the Medicare GLP-1 Bridge ($50 copay, July 1, 2026), and Foundayo’s approval — confirmed via CMS, KFF, Eli Lilly, CNBC, and NovoCare/LillyDirect (and flagged as fast-changing).

Next scheduled review: July 15, 2026 for FDA status and prices; a full patent re-check each quarter.

Frequently asked questions